Organon & Co. (OGN) Aandelenanalyse

Bedrijfsoverzicht

Organon & Co. is a specialized pharmaceutical entity focused on developing and delivering women's health solutions through a portfolio of prescription therapies and medical devices across global markets including the United States, Europe, Canada, Japan, and various international regions. Operating within the Healthcare sector and specifically the Drug Manufacturers - General industry, the company leverages its operational footprint to address specific therapeutic needs through a comprehensive product range. The organization employs approximately 10,000 individuals and holds a market capitalization of $2.30 billion, reflecting its established position within the broader biopharmaceutical landscape. With annual revenue reported at $6.22 billion, the company demonstrates significant scale, indicating a substantial market presence and a capacity to generate substantial cash flows despite operating in a competitive therapeutic area.

Financiële gezondheid

The company reported a total revenue of $6.22 billion over the trailing twelve months, generating net income of $187.00 million and an EBITDA of $1.65 billion. The substantial gap between the $6.22 billion revenue figure and the $187.00 million net income reveals a cost structure where operating expenses, including cost of goods sold and administrative costs, consume approximately 97% of gross revenue before reaching the bottom line. Despite the high operating costs, the entity maintains a free cash flow of $190.12 million, which provides a critical buffer for financial flexibility, allowing management to fund operations, service debt, or pursue strategic initiatives without relying solely on external capital markets. Profitability metrics show a gross margin of 54.3%, indicating efficient production and pricing power for its product lines; an operating margin of 16.2% suggests that roughly one-sixth of revenue remains after covering all operating expenses; and a profit margin of 3.0% reflects the final net income relative to sales. On the balance sheet, the company holds $574.00 million in cash against total debt of $8.80 billion, resulting in a debt-to-equity ratio of 1170.21, which characterizes a highly leveraged financial position typical of capital-intensive pharmaceutical firms. Liquidity is supported by a current ratio of 1.82, indicating that the company possesses $1.82 in current assets for every $1.00 of current liabilities, suggesting a comfortable ability to meet short-term obligations. Return on equity stands at 30.6%, while return on assets is 6.2%, metrics that collectively reveal management's effectiveness in generating returns relative to the shareholders' capital invested and the total asset base employed.

Waarderingsbeoordeling

Valuation multiples for Organon & Co. show a trailing P/E ratio of 12.26 and a forward P/E of 2.37. The stark difference between these two figures implies that the market expects a significant contraction in earnings in the near future, as the forward multiple is less than one-quarter of the trailing multiple. The price-to-book ratio is 3.06, indicating that the market values the company at more than three times its net asset value, which suggests a premium assigned to its intangible assets and future growth potential relative to its book equity. Alternative valuation metrics include a price-to-sales ratio of 0.37 and an EV/EBITDA of 6.36; the low price-to-sales figure highlights that the stock trades at a fraction of its revenue, while the EV/EBITDA provides a debt-adjusted perspective on earnings power. Regarding price volatility, the stock has a 52-week high of $13.24 and a 52-week low of $5.69. Given the current market context implied by the forward P/E, the stock is trading in a range that reflects significant downside from its recent peak, illustrating the market's adjustment to current earnings expectations. The company possesses a beta of 0.64, meaning its stock price tends to be less volatile than the broader market, moving only 64% as much as the market index during periods of fluctuation.

Growth & Income

Revenue growth for the trailing twelve months is recorded at -5.3%, while earnings growth is listed as N/A due to the specific reporting period constraints. The negative revenue growth indicates a contraction in top-line sales, whereas the absence of a reported earnings growth figure suggests that net income performance is not currently being highlighted as a growth metric in the available data. The company pays a dividend with a yield of 0.9% and maintains a payout ratio of 47.2%. This payout ratio indicates that the company distributes nearly half of its earnings to shareholders, a practice that must be evaluated carefully given the negative revenue growth and high leverage levels. With a forward P/E of 2.37, the market is pricing the stock on future expectations rather than current growth momentum, as the current earnings yield exceeds the dividend yield significantly. The overall growth and income profile is characterized by revenue contraction and a reliance on dividends that are substantial relative to the current earnings base.